title: A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.
abstract: Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing <1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P > 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P < 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses.
authors.affiliation: Addiction and Pharmacology Research Laboratory, California Pacific Medical Center, San Francisco, California, USA. gantt@cpmcri.org
authors.forename: G P
authors.initials: GP
authors.lastname: Galloway
authors.forename: R
authors.initials: R
authors.lastname: Buscemi
authors.forename: J R
authors.initials: JR
authors.lastname: Coyle
authors.forename: K
authors.initials: K
authors.lastname: Flower
authors.forename: J D
authors.initials: JD
authors.lastname: Siegrist
authors.forename: L A
authors.initials: LA
authors.lastname: Fiske
authors.forename: M J
authors.initials: MJ
authors.lastname: Baggott
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: D
authors.initials: D
authors.lastname: Polcin
authors.forename: C Y A
authors.initials: CY
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Mendelson
mesh_terms: D000328:Adult; D019969:Amphetamine-Related Disorders / Q000188:drug therapy; D003692:Delayed-Action Preparations; D003913:Dextroamphetamine / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008694:Methamphetamine / Q000009:adverse effects*
chemical_list: D003692:Delayed-Action Preparations; D008694:Methamphetamine; D003913:Dextroamphetamine